Name No. For Patients with Purpose
NRG GY019 21-29

Stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum.

“Low-grade” means that the cells in the tumour look more like normal cells under a microscope compared to “high-grade” tumours, which appear more abnormal. “Serous” refers to the type of cells involved, which are found in certain tissues. This type of cancer tends to grow slowly compared to other types, and it might not spread as quickly.

To examine if letrozole monotherapy/maintenance (L/L) is non-inferior to intravenous (IV) paclitaxel/carboplatin and maintenance letrozole (CT/L) with respect to progression-free survival (PFS) in women with stage II-IV primary low-grade serous carcinoma of the ovary or peritoneum after primary surgical cytoreduction.


Name No. For Patients with Purpose
“XPORT” – ENGOT-EN20/GOG-3083/XPORT-EC-042 22-08

p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma.

When we say someone has p53 wildtype cancer, it means their guardian (p53) is working as it should. It’s like having a strong and reliable guardian who can keep an eye on things and prevent trouble (like stopping cells from growing out of control).

So, in simple terms, p53 wildtype cancer means the guardian in the body is doing its job properly, but still, cancer has somehow developed.

The purpose of this study is to evaluate the efficacy and safety of Selinexor as a maintenance treatment in patients with p53 wildtype endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumours version 1.1 [RECIST v 1.1]) after completing at least 12 weeks of platinum-based therapy. A total of 220 participants will be enrolled in the study and randomised in a 1:1 ratio to maintenance therapy with either Selinexor or placebo.


Name No. For Patients with Purpose
HELP-ER 22-05

First platinum sensitive relapsed ovarian cancer

Prospective Study of HE4 serum Level in Patients with First Relapsed Ovarian Cancer. Improving the prediction of surgical outcome at secondary cytoreduction in patients with ovarian cancer. This study aims to improve upon the contemporary AGO score by including additional clinical variables like circulating HE4 and CA125 levels to predict surgical outcome at secondary cytoreduction.


Name No. For Patients with Purpose
OVHIPEC-2 20-07

Stage III Epithelial Ovarian Cancer

The objective of this study is to prove that treatment with primary cytoreductive surgery in combination with HIPEC (treatment arm) improves outcome compared to primary cytoreductive surgery without HIPEC (standard arm)